DEVELOPMENT OF A NEW ANTITUMOR INHIBITOR FROM SCORPION VENOM TARGETING THE HUMAN PLASMA TISSUE MATRIX METALLOPROTEINASE-2.
The purpose of this research is to develop new molecules for the therapy and diagnostics of MMP-2 expressing tumors such as glioblastoma. The goal of the 3-year project has been met: we developed a patentable 'lead compound' group that is superior to the start compound chlorotoxin in that it can target malignant tumor cells more efficiently and selectively than chlorotoxin does. We have filed a patent application for these compounds.
Our lead compound can also be used as a targeting molecule in chimeric antigen receptor (CAR) T-cell therapy.
On 15.11.2017, this project received a grant funding of HUF 496,355,200 from the National Office for Research, Development and Innovation under the grant ID KFI_16-2017-0524. With the funding intensity being 70,77%, the total cost of e project is HUF 701,380,000.